Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Undetectable circulating tumor DNA confirms the inability of pseudomyxoma peritonei to systemic dissemination.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology - 1 Jul 2024

Villarejo Campos P, Vázquez-Borrego M C, Martínez-Quintanilla J, Cabot D, Romero-Ruíz A, Granados-Rodríguez M, Bura F I, García-Arranz M, García-Olmo D, Arjona-Sánchez A

Abstract excerpt

The study of circulating tumor DNA (ctDNA) plays a pivotal role in advancing precision oncology, providing valuable information for individualized patient care and contributing to the ongoing effort to improve cancer diagnosis, treatment, and management. However, its applicability in pseudomyxoma peritonei (PMP) remains unexplored. In this multicenter retrospective study involving 21 PMP patients, we investigated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Chromogranins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Circulating Tumor DNA

Share to GTP-Binding Protein alpha Subunits, Gs

Share to Mutation

Share to Peritoneal Neoplasms

Share to Pilot Projects

Share to Proto-Oncogene Proteins p21(ras)

Source

Identifiers

PMID: 38735236
DOI: 10.1016/j.ejso.2024.108395

Genes

GNAS
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Undetectable circulating tumor DNA confirms the inability of pseudomyxoma peritonei to systemic dissemination.PMID 38735236Read ↗

Limited clinical utility of mutation-based circulating tumor DNA detection in pseudomyxoma peritonei.Semantic proximity Read ↗

Appendix-derived Pseudomyxoma Peritonei (PMP): Molecular Profiling Toward Treatment of a Rare Malignancy.Semantic proximity Read ↗

Genomic profile of pseudomyxoma peritonei analyzed using next-generation sequencing and immunohistochemistry.Semantic proximity Read ↗

Molecular profiles of high-grade and low-grade pseudomyxoma peritonei.Semantic proximity Read ↗

Targeted Genetic Sequencing Analysis of 223 Cases of Pseudomyxoma Peritonei Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Shows Survival Related to GNAS and KRAS Status.Semantic proximity Read ↗

Precision Oncology and Systemic Targeted Therapy in Pseudomyxoma Peritonei.Semantic proximity Read ↗

Analysis of Mutation and Loss of Heterozygosity by Whole-Exome Sequencing Yields Insights into Pseudomyxoma Peritonei.Semantic proximity Read ↗

The mutational landscape and prognostic indicators of pseudomyxoma peritonei originating from the ovary.Semantic proximity Read ↗

Progress on immuno-microenvironment and immune-related therapies in patients with pseudomyxoma peritonei.Semantic proximity Read ↗

GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study.Semantic proximity Read ↗

The utility of ctDNA in colorectal cancer with peritoneal metastases.Semantic proximity Read ↗

Cross-laboratory replication of pseudomyxoma peritonei tumor microbiome reveals reproducible microbial signaturesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.